The first and only treatment for early-onset, severe or serious 5-FU toxicity^{1, 2, 19}

Vistogard® (uridine triacetate) oral granules—a documented safety profile^{1, 2, 19}

Treat with confidence

Adverse reactions occurring in >2% of patients (N=135)
Adverse Reactions	Number of Patients	Percent of Patients
Vomiting	13	10%
Nausea	7	5%
Diarrhea	4	3%

No contraindications, warnings, precautions, or cytochrome P450 drug–drug interactions⁴
May be taken without regard to meals⁴
Pharmacokinetics were not significantly affected by gender or age (in patients aged 20 to 83 years)⁴
Geriatric patients: Of the 135 patients in clinical studies with Vistogard®, 30% were ≥65, including 11% ≥75
One patient receiving Vistogard® had Grade 3 nausea and vomiting⁴
Vistogard® was discontinued for adverse reactions in 2 (1.4%) patients⁴

Indication

VISTOGARD is indicated for the emergency treatment of adult and pediatric patients:

following a fluorouracil or capecitabine overdose regardless of the presence of symptoms, or
who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration.

Limitations of use

VISTOGARD is not recommended for the non–emergent treatment of adverse reactions associated with fluorouracil or capecitabine because it may diminish the efficacy of these drugs.
The safety and efficacy of VISTOGARD initiated more than 96 hours following the end of fluorouracil or capecitabine administration have not been established.

SERB® and the SERB logo are registered trademarks of SERB S.à.r.l.

Vistogard® a registered trademark of of BTG International Inc.

If you wish to report an adverse event or product quality complaint, please call 1-877-377-3784.

You are encouraged to report side effects of prescription drugs to the FDA.
Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.

BTG Specialty Solutions Center™

1-844-293-0007 (Voice)

1-877-626-9910 (Fax)

24-hour Medical Information

1-877-377-3784 (Voice)

The first and only treatment for early-onset, severe or serious 5-FU toxicity 1, 2, 19

Vistogard® (uridine triacetate) oral granules—a documented safety profile 1, 2, 19

Treat with confidence

Indication

You are now leaving the patient site.

The first and only treatment for early-onset, severe or serious 5-FU toxicity^{1, 2, 19}

Vistogard® (uridine triacetate) oral granules—a documented safety profile^{1, 2, 19}